Create a narrative

CytomX Therapeutics Community

NasdaqGS:CTMX Community

1 Narratives written by author
0 Comments on narratives written by author
15 Fair Values set on narratives written by author

Create a narrative

CytomX Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Advancement Of CX-2051 And CX-801 Will Open New Oncology Opportunities But Could Face Significant Risks

Key Takeaways Advancing programs CX-2051 and CX-801 into trials positions CytomX to address unmet oncology needs, potentially boosting future revenue. Strategic collaborations and milestone achievements with partners support sustained revenue streams and potential revenue growth.

US$4.75

FV

83.1% undervalued

-33.78%

Revenue growth p.a.

0

0

11

4 days ago